DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Nexavar (Sorafenib) - Published Studies

 
 



Nexavar Related Published Studies

Well-designed clinical trials related to Nexavar (Sorafenib)

AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. [2012]

Sorafenib in locally advanced or metastatic breast cancer. [2012]

Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. [2012]

Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy. [2011.12]

Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. [2011.08.11]

In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp. [2011.07.01]

An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. [2011.07]

Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study. [2011.07]

Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. [2011.06.20]

Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. [2011.06]

Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. [2011.04.12]

Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib. [2011.03.01]

[Randomize trial of cisplatin plus gemcitabine with either sorafenib or placebo as first-line therapy for non-small cell lung cancer]. [2011.03]

Sorafenib: activity and clinical application in patients with hepatocellular carcinoma. [2011.02]

Role of cetuximab and sorafenib in treatment of metastatic colorectal cancer. [2011.01]

Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. [2011]

Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. [2011]

Sorafenib: activity and clinical application in patients with hepatocellular carcinoma. [2011]

Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment? [2010.12]

Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. [2010.11.17]

Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. [2010.10.01]

Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. [2010.09]

Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET. [2010.09]

Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. [2010.08]

Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study. [2010.07]

Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib. [2010.05.25]

Sorafenib for the treatment of advanced hepatocellular carcinoma. [2010.05]

Incidence of brain metastases in renal cell carcinoma treated with sorafenib. [2010.05]

Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. [2010.04.10]

Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials. [2010.03]

Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. [2010.02.20]

A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. [2010.02]

Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. [2010.01.01]

Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma. [2010.01]

Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. [2010]

Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. [2010]

Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. [2010]

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. [2009.07.10]

Sorafenib tosylate in advanced kidney cancer: past, present and future. [2009.07]

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. [2009.06.10]

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. [2009.03.10]

[Palliative management of hepatocarcinoma with sorafenib (Nexavar). Results of the SHARP study (sorafenib hepatocarcinoma assessment randomized protocol trial)] [2009.03]

Sorafenib for the treatment of unresectable hepatocellular carcinoma. [2009.01]

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. [2009.01]

Sorafenib: a review of its use in advanced hepatocellular carcinoma. [2009]

Sorafenib for the treatment of unresectable hepatocellular carcinoma. [2008.12]

Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. [2008.11.26]

Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. [2008.10.15]

Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. [2008.10.01]

Sorafenib in advanced hepatocellular carcinoma. [2008.07.24]

Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. [2008.05.01]

Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. [2008.04]

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. [2008.02.06]

Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma. [2008.01.15]

Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. [2008.01.15]

Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. [2007.11.26]

Sorafenib TARGET trial results in Spanish patients. [2007.10]

Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview. [2007.09]

Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. [2007.06]

A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics. [2007.05]

Sorafenib in advanced clear-cell renal-cell carcinoma. [2007.01.11]

Randomized discontinuation trial of sorafenib (BAY 43-9006). [2006.10]

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. [2006.09.04]

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. [2006.06.01]

Well-designed clinical trials possibly related to Nexavar (Sorafenib)

Chemoembolization for hepatocellular carcinoma. [2012]

Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib. [2011.12]

Evolving molecular mechanism-based strategies for control of hepatocellular carcinoma. [2011.10.01]

Cautions regarding the fitting and interpretation of survival curves: examples from NICE single technology appraisals of drugs for cancer. [2011.10]

Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis. [2011.06]

Targeted therapies for thyroid tumors. [2011.04]

Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1. [2011.01]

Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. [2011]

Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1. [2011]

Pazopanib in renal cell carcinoma. [2010.12.15]

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. [2010.09.15]

Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib. [2010.08.10]

[Hepatocellular carcinoma] [2010.07]

Pazopanib in renal cell carcinoma. [2010]

Everolimus: in advanced renal cell carcinoma. [2009.10.22]

Role of everolimus in the treatment of renal cell carcinoma. [2009.10]

Lessons learned from independent central review. [2009.01]

Everolimus: in advanced renal cell carcinoma. [2009]

New pharmacological developments in the treatment of hepatocellular cancer. [2009]

Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo. [2008.09]

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. [2008.08.09]

Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo. [2008.06.20]

Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy. [2008]

Mechanisms of hypertension associated with BAY 43-9006. [2006.03.20]

Kinase inhibition with BAY 43-9006 in renal cell carcinoma. [2004.09.15]

Other research related to Nexavar (Sorafenib)

Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence. [2012]

Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice. [2012]

Cryotherapy is associated with improved clinical outcomes of Sorafenib therapy for advanced hepatocellular carcinoma. [2012]

Sorafenib for treatment of hepatocellular carcinoma: a systematic review. [2012]

Sorafenib in melanoma. [2012]

Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. [2012]

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. [2012]

Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). [2012]

Sorafenib in hepatocellular carcinoma - a post marketing evaluation. [2012]

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. [2011]

Feasibility of (125)I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma. [2010.11]

A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma. [2010.09.14]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014